As pharmacy benefit costs continue to rise, appropriate diagnosis remains a critical component of responsible specialty drug and utilization management…
Our latest market review found migraine therapy costs increased 21.7% year over year, while claims rose 10.8%, highlighting the impact of newer, high-cost CGRP therapies…
On August 10, 2026, President Trump signed an executive order introducing a new framework for federal childhood vaccine recommendations, categorizing vaccines into three groups…
Specialty drugs now represent more than 50% of total drug spending across pharmacy and medical benefits combined, despite being used by a small percentage of members…
A significant shift in the inflammatory disease market is underway as Pfizer's Xeljanz® (tofacitinib) now faces broad generic competition. With discounts reaching…
